Legend Biotech Corporation (LEGN) has released an update.
Legend Biotech Corporation has reported promising first quarter 2024 financial results, with significant growth in CARVYKTI® sales and strategic expansions, including a new agreement with Novartis for increased manufacturing capacity. The company’s advancements have led to label expansions in multiple regions, positioning CARVYKTI® to reach more patients with multiple myeloma. With a strong cash reserve, Legend Biotech is poised for continued growth and anticipates turning an operating profit by 2026.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com